Biblio
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol. 2021;8(8):e562-e571.
Pretransplant minimal residual disease predicts survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant. 2015.
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Hematology Am Soc Hematol Educ Program. 2014;2014(1):151-157.
.